Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 2Stomatitis 1Neoplasms 1Neoplasm Metastasis 1Lupus Nephritis 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia 1Inflammation 1Fatigue Syndrome, Chronic 1Bone Neoplasms 1Bites and Stings 1Arthritis, Rheumatoid 1

Interventions

Gemcitabine 34pembrolizumab 27Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Etanercept × Clear all
NCT00031551 2017-12-06

Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
27 enrolled 10 charts

Inflammation, Neoplasms, Stomatitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡